ReviewCancers2022
Hobnail Papillary Thyroid Carcinoma, A Systematic Review and Meta-Analysis.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- P53 loss and BRAF V600E mutation suggest potentially divergent pathways to aggressiveness in high grade differentiated thyroid carcinoma.Discover oncology · 2026Article
- Prognostic factors evaluated in differentiated thyroid carcinomas.Endocrine connections · 2026Review
- Predictive Factors of Lymph Node Metastasis in Papillary Thyroid Microcarcinoma (PTMC).Medicina (Kaunas, Lithuania) · 2025Article
- Association BetweenCancers · 2025Article
- BRAF V600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression.Endocrine connections · 2025Article
- Article
- The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies.International journal of molecular sciences · 2025Review
- Predictive risk-scoring model for lateral lymph node metastasis in papillary thyroid carcinoma.Scientific reports · 2025Article
- Prognostic factors of papillary and follicular carcinomas based on pre-, intra-, and post-operative findings.European thyroid journal · 2024Review
- The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review.Journal of personalized medicine · 2024Review
- The Heinous Hobnail: A Case Report of the Rare Hobnail Variant of Papillary Thyroid Carcinoma.Cureus · 2024Article
- Article
- PROGNOSTIC IMPLICATIONS OF HOBNAIL CELL MORPHOLOGY IN PAPILLARY THYROID CARCINOMA: A CLINICOPATHOLOGICAL ANALYSIS.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although papillary thyroid carcinoma (PTC) is considered to have an excellent prognosis, some recently identified more aggressive variants show reduced overall survival rates. Hobnail PTC (HPTC) was newly recognized as one of these aggressive forms, affecting recurrence, metastasis, and overall survival rates. Herein, we performed a systematic review and meta-analysis of studies including cases or case series with patients with HPTC. Furthermore, we included our individual case series consisting of six patients. The pooled mortality rate in the cohort, consisting of 290 patients, was 3.57 (95% CI 1.67−7.65) per 100 person/years. No sex differences could be observed concerning mortality (p = 0.62), but older age and tumor size significantly affected mortality (p = 0.004 and p = 0.02, respectively). The percentage of hobnail cells did not affect mortality (p = 0.97), neither did the presence of BRAF mutations. Classical characteristics such as the presence of extrathyroidal extension (p = 0.001), distant metastases (p < 0.001), and lymph node metastases (p < 0.001) all had a significant impact on mortality. Thus, HPTC appears to correlate with worse overall survival, and all PTC cases should be carefully assessed for this variant.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.